Neurocrine Biosciences Inc (NBIX) — Cash Flow Reinvestment Rate
Neurocrine Biosciences Inc (NBIX) has a Cash Flow Reinvestment Rate of 0.15x as of December 2025, reinvesting $57.70 Million (capex $2.40 Million plus investments $-55.30 Million) from operating cash flow of $388.40 Million. Explore NBIX capital reinvestment ratio to see what proportion of operating cash flow is directed to capital expenditures.
Reinvestment Rate
Total Reinvested
Operating Cash Flow
Capital Expenditures
Neurocrine Biosciences Inc Cash Flow Reinvestment Rate (1996–2025)
Historical reinvestment intensity for Neurocrine Biosciences Inc across 12 annual periods. Also explore NBIX total assets for the complete picture of this company's asset base.
Annual Cash Flow Reinvestment Rate for Neurocrine Biosciences Inc (1996–2025)
Year-by-year capital reinvestment analysis for Neurocrine Biosciences Inc. For live market cap and broader valuation context, see NBIX market cap overview.
| Year | Reinvestment Rate | Total Reinvested (USD) | Operating CF | Capex | YoY Change |
|---|---|---|---|---|---|
| 2025 | 0.34x | $264.40 Million | $782.70 Million | $34.00 Million | ▲ +21.9% |
| 2024 | 0.28x | $165.00 Million | $595.40 Million | $38.20 Million | ▼ -73.6% |
| 2023 | 1.05x | $409.20 Million | $389.90 Million | $28.30 Million | ▲ +181.1% |
| 2022 | 0.37x | $126.70 Million | $339.40 Million | $16.50 Million | ▼ -23.8% |
| 2021 | 0.49x | $125.60 Million | $256.50 Million | $23.40 Million | ▲ +332.0% |
| 2020 | 0.11x | $25.90 Million | $228.50 Million | $10.90 Million | ▼ -88.3% |
| 2019 | 0.97x | $142.18 Million | $147.00 Million | $14.70 Million | ▼ -59.6% |
| 2018 | 2.40x | $242.94 Million | $101.40 Million | $24.80 Million | ▲ +37885.7% |
| 2010 | 0.01x | $315.00K | $49.94 Million | $315.00K | ▼ -99.5% |
| 2003 | 1.36x | $50.44 Million | $37.13 Million | $50.44 Million | ▲ +133.5% |
| 1997 | 0.58x | $6.40 Million | $11.00 Million | $6.40 Million | ▲ +143.6% |
| 1996 | 0.24x | $1.60 Million | $6.70 Million | $1.60 Million | — |